Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 1997

View Archived Issues

Abbott's newest dopaminergic compounds described in patent literature

5-HT4 antagonists disclosed by Taisho

Cephems in development at Meiji Seika

Cell migration inhibitors from Teijin

Japanese researchers develop new HIV protease inhibitors

Magainin analogues reported by Scripps

Pollakiuria treatment described by SS Pharm.

Tanabe Seiyaku discloses novel antinephritic compounds

Egis develops 5-LO inhibitors

Antitumor prodrugs for ADEPT from Pharmachemie

BTG describes immunosuppressive antibodies

BASF discloses antithrombotic from ticks

Lilly/Novo Nordisk discover candidate for IBS

Clinical trial data reported for meningitis vaccine

Another approval for first-line Abelcet

Hemosol discloses novel cellular immunotherapeutic procedure

Genzyme acquires PharmaGenics and forms new division

LifeTECH and Pall announce collaboration

Abgenix reports significant advance in human antibody technology

First Corlopam Renal Program study completed

Access/Dow collaborate on contrast agents and radiopharmaceuticals

Sugen's TK antagonist enters phase II

Antiobesity agent from Neurogen/Pfizer advances to multiple-dose trials

Whole-body hyperthermia therapy enters clinic for new indication

FDA approval for Ferring antifertility Rx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...